Evidence map›Paper›PMID 31548348›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

ImmunoPET, [

Sargur Madabushi Srideshikan, Jamison Brooks, Darren Zuro, Bijender Kumar, James Sanchez, Liliana Echavarria Parra, Marvin Orellana, Paresh Vishwasrao, Indu Nair, Junie Chea and 13 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. In Vitro and In Vivo Characterization ofMolecules (Basel, Switzerland) · 2022
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33.International journal of molecular sciences · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

Sargur Madabushi SrideshikanDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, California.
Jamison BrooksDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, California.
Darren ZuroDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, California.
Bijender KumarDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, California.
James SanchezBeckman Research Institute of City of Hope, Duarte, California.
Liliana Echavarria ParraDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, California.
Marvin OrellanaDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, California.
Paresh VishwasraoDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, California.
Indu NairDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, California.
Junie CheaDepartment of Molecular Imaging & Therapy, Beckman Research Institute of City of Hope, Duarte, California.
Kofi PokuDepartment of Molecular Imaging & Therapy, Beckman Research Institute of City of Hope, Duarte, California.
Nicole BowlesDepartment of Molecular Imaging & Therapy, Beckman Research Institute of City of Hope, Duarte, California.
Aaron MillerDepartment of Molecular Imaging & Therapy, Beckman Research Institute of City of Hope, Duarte, California.ORCID 0000-0003-4214-5921
Todd EbnerDepartment of Molecular Imaging & Therapy, Beckman Research Institute of City of Hope, Duarte, California.
Justin MolnarDepartment of Molecular Imaging & Therapy, Beckman Research Institute of City of Hope, Duarte, California.
Joseph RosenthalDepartment of Pediatrics, City of Hope National Medical Center, Duarte, California.
Daniel A ValleraDepartment of Therapeutic Radiology-Radiation Oncology, University of Minnesota, Minneapolis, Minnesota.
Jeffrey Y C WongDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, California.
Anthony S SteinDepartment of Hematology/HCT, City of Hope National Medical Center, Duarte, California.
David ColcherDepartment of Molecular Imaging & Therapy, Beckman Research Institute of City of Hope, Duarte, California.
John E ShivelyDepartment of Molecular Imaging & Therapy, Beckman Research Institute of City of Hope, Duarte, California.
Paul J YazakiDepartment of Molecular Imaging & Therapy, Beckman Research Institute of City of Hope, Duarte, California.
Susanta K HuiDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, California. shui@coh.org.
City Of Hope National Medical Center · USUniversity of Minnesota · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
Conformal Total Body and Marrow Irradiation for LeukemiaR01CA154491 · NCI · UNIVERSITY OF MINNESOTA · PI HUI, SUSANTA K, WONG, JEFFREY Y · 2011 to 2024
$5.0M
NCI NIH HHS P01 CA111412NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA154491
6 · The paper itself

Abstract

purposeAcute myeloid leukemia (AML) is a highly aggressive form of leukemia, which results in poor survival outcomes. Currently, diagnosis and prognosis are based on invasive single-point bone marrow biopsies (iliac crest). There is currently no AML-specific noninvasive imaging method to detect disease, including in extramedullary organs, representing an unmet clinical need. About 85% to 90% of human myeloid leukemia cells express CD33 cell surface receptors, highlighting CD33 as an ideal candidate for AML immunoPET. EXPERIMENTAL

designWe evaluated whether [

results[

conclusionsWe have successfully developed a novel anti-CD33 immunoPET-CT-based noninvasive modality for AML and its spatial distribution, indicating a preferential skeletal niche.

Indexed as

AnimalsAntibodies, Monoclonal, HumanizedCell Line, TumorCopper RadioisotopesDisease Models, AnimalHeterocyclic Compounds, 1-RingImmunoconjugatesLeukemia, Myeloid, AcuteMiceMice, Inbred NODMice, SCIDPositron Emission Tomography Computed TomographyRadiopharmaceuticalsSialic Acid Binding Ig-like Lectin 3Tissue DistributionXenograft Model Antitumor Assays1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidAntibodies, Monoclonal, HumanizedCD33 protein, humanCopper RadioisotopesHeterocyclic Compounds, 1-RingImmunoconjugatesRadiopharmaceuticalsSialic Acid Binding Ig-like Lectin 3

Identifiers

PMID31548348
PMCPMC6911626
OpenAlexW2975857652

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.